Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets. However, discoveries have been limited by small sample sizes (n<5,000) due to the complexity of measuring PR. We trained a model to predict PR from complete blood count (CBC) scattergrams. A GWAS of this phenotype in 29,806 blood donors identified 21 distinct associations implicating 20 genes, of which six have been identified previously. The effect size estimates were significantly correlated with estimates from a study of flow-cytometry measured PR and a study of a phenotype of in vitro thrombus formation. A genetic score of PR built from the 21 variants was associated with myocardial infarction and pulmonary embolism. Mendelian randomisat...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...
Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets....
Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets....
Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets....
To access publisher's full text version of this article, please click on the hyperlink in Additional...
Cardiovascular genomic consists in the identification of polymorphic genes responsible for the susce...
Cardiovascular genomic consists in the identification of polymorphic genes responsible for the susce...
Cardiovascular genomic consists in the identification of polymorphic genes responsible for the susce...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...
Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets....
Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets....
Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug targets....
To access publisher's full text version of this article, please click on the hyperlink in Additional...
Cardiovascular genomic consists in the identification of polymorphic genes responsible for the susce...
Cardiovascular genomic consists in the identification of polymorphic genes responsible for the susce...
Cardiovascular genomic consists in the identification of polymorphic genes responsible for the susce...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Objective Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is th...
Many drugs are nowadays available to inhibit platelet activation and aggregation, especially in pati...